Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00458042 · ClinicalTrials.gov registry record · Phase 4

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

A Phase 4 study, sponsored by United Therapeutics.

Terminated
Registry status
Phase 4
Development phase
10
Enrollment target

NCT00458042: Clinical Trial Phase 4 study, sponsored by United Therapeutics.

NCT00458042 is a Phase 4 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00458042, a Phase 4 study, was terminated before completion, sponsored by United Therapeutics.

TERMINATED
Registry status
Phase 4
Development phase
10 participants
Enrollment target

Study Summary

The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy. This study is intended to provide information on the safe transition from Ventavis to Remodulin as well as the impact intravenous Remodulin may have on overall quality of life and treatment satisfaction compared to Ventavis.

Interventions

  • DRUG treprostinil sodium

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2007-03
Est. Completion 2007-11
Phase Phase 4
United Therapeutics

63 total trials

Why NCT00458042 stopped before completion

NCT00458042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which treprostinil sodium is the first listed.

NCT00458042 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00458042 about?

NCT00458042 is a clinical study titled "Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction". The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy. This study is intended to provide information on the safe transition from Ventavis to Remodulin as well as the im...

What is the current status of trial NCT00458042?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2007-03. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00458042?

The interventions under investigation include: treprostinil sodium (DRUG).

Who is sponsoring clinical trial NCT00458042?

This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00458042's enrollment target sits among peer trials

10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00458042, the US trial registry maintained by the National Library of Medicine. NCT00458042 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.